The evolving role of immuno‐oncology for the treatment of head and neck cancer

Monoclonal antibodies (mAbs) that target immune co‐signaling pathways have the potential to enable immune mediated tumor eradication. While early adoption of these agents for the treatment of advanced squamous cell carcinoma of the head and neck (SCCHN) has produced some astounding clinical successe...

Descripción completa

Detalles Bibliográficos
Autores principales: Strome, Arianna L., Zhang, Xiaoyu, Strome, Scott E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2019
Materias:
Head and Neck, and Tumor Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6383301/
https://www.ncbi.nlm.nih.gov/pubmed/30828620
http://dx.doi.org/10.1002/lio2.235
_version_ 1783396819227639808
author Strome, Arianna L.
Zhang, Xiaoyu
Strome, Scott E.
author_facet Strome, Arianna L.
Zhang, Xiaoyu
Strome, Scott E.
author_sort Strome, Arianna L.
collection PubMed
description Monoclonal antibodies (mAbs) that target immune co‐signaling pathways have the potential to enable immune mediated tumor eradication. While early adoption of these agents for the treatment of advanced squamous cell carcinoma of the head and neck (SCCHN) has produced some astounding clinical successes, the majority of patients fail to respond to therapy. The purpose of this review is to first provide a broad overview of the immuno‐oncology (I‐O) landscape and to then focus on the current status of mAb‐based I‐O (mAb:I‐O) for the treatment of SCCHN, with particular attention to the development of strategies for improving treatment responses.
format Online
Article
Text
id pubmed-6383301
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley & Sons, Inc.
record_format MEDLINE/PubMed
spelling pubmed-63833012019-03-01 The evolving role of immuno‐oncology for the treatment of head and neck cancer Strome, Arianna L. Zhang, Xiaoyu Strome, Scott E. Laryngoscope Investig Otolaryngol Head and Neck, and Tumor Biology Monoclonal antibodies (mAbs) that target immune co‐signaling pathways have the potential to enable immune mediated tumor eradication. While early adoption of these agents for the treatment of advanced squamous cell carcinoma of the head and neck (SCCHN) has produced some astounding clinical successes, the majority of patients fail to respond to therapy. The purpose of this review is to first provide a broad overview of the immuno‐oncology (I‐O) landscape and to then focus on the current status of mAb‐based I‐O (mAb:I‐O) for the treatment of SCCHN, with particular attention to the development of strategies for improving treatment responses. John Wiley & Sons, Inc. 2019-01-10 /pmc/articles/PMC6383301/ /pubmed/30828620 http://dx.doi.org/10.1002/lio2.235 Text en © 2019 The Authors. Laryngoscope Investigative Otolaryngology published by Wiley Periodicals, Inc. on behalf of The Triological Society. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Head and Neck, and Tumor Biology
Strome, Arianna L.
Zhang, Xiaoyu
Strome, Scott E.
The evolving role of immuno‐oncology for the treatment of head and neck cancer
title The evolving role of immuno‐oncology for the treatment of head and neck cancer
title_full The evolving role of immuno‐oncology for the treatment of head and neck cancer
title_fullStr The evolving role of immuno‐oncology for the treatment of head and neck cancer
title_full_unstemmed The evolving role of immuno‐oncology for the treatment of head and neck cancer
title_short The evolving role of immuno‐oncology for the treatment of head and neck cancer
title_sort evolving role of immuno‐oncology for the treatment of head and neck cancer
topic Head and Neck, and Tumor Biology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6383301/
https://www.ncbi.nlm.nih.gov/pubmed/30828620
http://dx.doi.org/10.1002/lio2.235
work_keys_str_mv AT stromeariannal theevolvingroleofimmunooncologyforthetreatmentofheadandneckcancer
AT zhangxiaoyu theevolvingroleofimmunooncologyforthetreatmentofheadandneckcancer
AT stromescotte theevolvingroleofimmunooncologyforthetreatmentofheadandneckcancer
AT stromeariannal evolvingroleofimmunooncologyforthetreatmentofheadandneckcancer
AT zhangxiaoyu evolvingroleofimmunooncologyforthetreatmentofheadandneckcancer
AT stromescotte evolvingroleofimmunooncologyforthetreatmentofheadandneckcancer

Ejemplares similares